A Country That Recalls Its Own Forgetting
Between the 1930s and 1960s, Italian clinics ran psychedelic experiments on hundreds of patients, then forgot they ever happened. Now a new generation of researchers, clinicians, and harm reduction advocates is rebuilding that work, and facing a decision the United States never had to: whether these therapies enter the public health system or stay with those who can pay. The post A Country That Recalls Its Own Forgetting appeared first on Psychedelics Today.
External link. We are not responsible for the content.
Read more ↗More From Psychedelics Today
Weekly Psychedelic Policy Briefing – August 9, 2026
Jack Gorsline, investigative journalist, covers four federal developments this week. The Department of Veterans Affai...
Ibogaine’s Moment Has Arrived. Are We Ready to Meet It?
MAPS co-executive director Ismail Lourido Ali on what the April 2026 executive order, the Texas and Colorado funding ...
The Post-Psychedelic Challenges Study: A Vital New Frontier in Psychedelic Science
An Emory study is recruiting 800 people who faced post-psychedelic challenges, to learn what recovery actually takes....
Latest News
Microdosing for Anxiety: What the Evidence Shows, and Where It Doesn’t
Microdosing for anxiety looks encouraging in open-label surveys and far less convincing under placebo control. What f...
The Toads Didn’t Consent to Being Milked, Sorry
Chasing "enlightenment" at the expense of desert toads is not the flex you think it is. [...] Read More... The post T...
Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing
For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Ey...
Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High
Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the...
MAPS Responds to Report of Progress for MDMA-assisted therapy for PTSD with FDA
August 10, 2026 — The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today responded to an A...
Why don’t some people respond to psychedelics? 5 Questions for psychologist Rachel Ham
Ham discusses doing interviews with clinical trial participants who didn’t experience substantial benefits.